

Exhibit 16**US Chronic Myeloid Leukemia (CML) Therapies****AWP Annual Patient Cost (\$)**

<u>Company/US Launch</u>	<u>Gleevec</u> Novartis (2001)	<u>Sprycel</u> Bristol-Myers (2006)	<u>Tasigna</u> Novartis (2007)
2005	\$35,734	-	-
2006	38,572	\$64,496	-
2007	41,619	76,739	\$83,238
2008	48,050	80,006	\$91,395
2009	55,395	92,411	105,420
2010	66,991	111,613	115,856
2011	77,305	115,074	119,448
2012	93,368	125,299	125,300
2013	101,772	129,058	129,686
2014	122,361	140,662	142,707
2015	147,788	151,211	151,269
2016	147,788	164,966	164,942
2017	147,788	176,348	180,941
2018	\$147,788	\$188,516	\$198,854

Source: Redbook/Truven.

From the SDNY Whistleblower Complaint filed August 3, 2018